Onconetix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Onconetix, Inc. on October 29, 2025, regarding events occurring on October 23, 2025. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Cincinnati, Ohio. The filing addresses the scheduling of the 2025 Annual Meeting of Stockholders and the associated deadlines for shareholder proposals and director nominations.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder meeting logistics rather than financial performance.
Material Changes
The Board of Directors determined on October 23, 2025, that the 2025 Annual Meeting will be held on December 5, 2025, at 10:00 a.m. Eastern Time. The meeting location is the offices of Ellenoff Grossman & Schole LLP in New York, NY. This date is more than 60 days subsequent to the anniversary of the previous year's Annual Meeting, triggering specific disclosure requirements under Rule 14a-8.
Guidance, Outlook, and Corporate Actions
- Annual Meeting Date: December 5, 2025.
- Rule 14a-8 Proposal Deadline: Stockholder proposals must be received by the close of business on November 10, 2025, to be included in the proxy materials.
- Director Nomination Deadline: Advance notice for director nominations must be received by the close of business on November 10, 2025.
- Universal Proxy Rules: Stockholders intending to solicit proxies for director nominees other than the Company's nominees must provide notice by November 10, 2025.
- Adjournment Policy: Public announcement of an adjournment or postponement will not extend the time period for submitting Rule 14a-8 proposals.
Key Facts for Investor Verification
- Verify the exact date and location of the 2025 Annual Meeting (December 5, 2025, New York, NY).
- Confirm the November 10, 2025, deadline for submitting shareholder proposals and director nominations.
- Note that the filing is signed by Karina M. Fedasz, serving as Interim Chief Executive Officer and Interim Chief Financial Officer.
- Review the Preliminary Proxy Statement on Schedule 14A filed on October 29, 2025, for additional details referenced in this report.